Mizuho initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $51 price target The company’s lead asset, TX45, is a ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...

(MENAFN- GlobeNewsWire - Nasdaq) Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ...

The presentation will highlight Phase 1b data for TX45, Tectonic’s lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF.

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN ...

The report also covers the potential for relaxin-related treatments that could boost confidence in TECX's TX45, a RXFP1 agonist, ahead of its Phase 1b readout. Piper Sandler has identified six ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort WATERTOWN, Mass., ...